Breaking News Instant updates and real-time market news.

EXEL

Exelixis

$12.95

-0.23 (-1.75%)

08:26
10/10/16
10/10
08:26
10/10/16
08:26

Leerink says ESMO raises confidence in potential label expansions at Exelixis

Following several oral and poster presentations this weekend at the ESMO cancer meeting, Leerink analyst Michael Schmidt said he has greater confidence regarding several potential label expansion opportunities for Exelixis' two products, Cabometyx and Cotellic. Cabometyx is "very well positioned" to capture significant market share and consensus expectations for Cotellic are only modest, believes Schmidt, who keeps an Outperform rating on Exelixis shares.

  • 10

    Oct

  • 10

    Oct

EXEL Exelixis
$12.95

-0.23 (-1.75%)

08/04/16
STFL
08/04/16
NO CHANGE
STFL
Exelixis price target raised to $12 from $10 at Stifel
Stifel analyst Stephen Willey raised his price target on Exelixis after the company reported significantly better than expected Cabometyx and residual/off-label Cometriq sales into the newly launched indication of refractory renal cell carcinom. Willey expects the results to improve investors' confidence towards the company's growth outlook, and he says that anticipation of front-line CABOSUN results places a near-term floor on the stock. The analyst keeps a Buy rating on the shares.
08/22/16
GSCO
08/22/16
NO CHANGE
GSCO
Goldman lists companies to be in focus after Medivation deal
After Pfizer (PFE) announced it has agreed to acquire Medivation (MDVN) for $81.50 per share in cash, Goldman Sachs analyst Salveen Richter said he expects a focus on other commercial small-to-mid-cap cancer companies, including Incyte (INCY), Seattle Genetics (SGEN), ARIAD (ARIA) and Exelixis (EXEL). Also noting that Sanofi (SNY), which was pursuing Medivation, has recently suggested an interest in a rare disease transaction up to potentially as large as $20B, he would expect rare disease companies of that size - such as BioMarin (BMRN), Amicus (FOLD) and Ultragenyx (RARE) - to be in focus as well.
09/28/16
LEER
09/28/16
NO CHANGE
LEER
Exelixis selloff overdone, says Leerink
09/28/16
LEER
09/28/16
NO CHANGE
LEER
Outperform
Exelixis selloff based on ESMO abstracts overdone, says Leerink
Leerink analyst Michael Schmidt believes Exelixis' selloff following the publication of ESMO poster abstracts is overdone. The analyst notes that abstract includes updated data from a Phase Ib trial evaluating the combination of axitinib with pembrolizumab and appears to have sparked competitive concerns for Exelixis. However, he believes it is highly premature to draw conclusions at this point on the company's Cabometyx' market opportunity or potential in Renal Cell Carcinoma. Schmidt reiterates an Outperform rating on the shares. In afternoon trading, Exelixis' stock has dropped over 15% to $13.12 per share.

TODAY'S FREE FLY STORIES

GS

Goldman Sachs

$249.02

1.67 (0.68%)

, TAL

TAL Education

$85.58

0.33 (0.39%)

13:51
02/27/17
02/27
13:51
02/27/17
13:51
Hot Stocks
Breaking Hot Stocks news story on Goldman Sachs, TAL Education »

Goldman Sachs reports…

GS

Goldman Sachs

$249.02

1.67 (0.68%)

TAL

TAL Education

$85.58

0.33 (0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

  • 03

    Mar

MYGN

Myriad Genetics

$18.98

-0.07 (-0.37%)

, VCYT

Veracyte

$7.95

0.06 (0.76%)

13:50
02/27/17
02/27
13:50
02/27/17
13:50
Recommendations
Myriad Genetics, Veracyte analyst commentary  »

Piper sees CMS halt of…

MYGN

Myriad Genetics

$18.98

-0.07 (-0.37%)

VCYT

Veracyte

$7.95

0.06 (0.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

13:50
02/27/17
02/27
13:50
02/27/17
13:50
General news
Treasury Action: yield have spiked higher as rate hike fears flare up »

Treasury Action: yield…

LJPC

La Jolla

$19.87

1.65 (9.06%)

13:39
02/27/17
02/27
13:39
02/27/17
13:39
Recommendations
La Jolla price target raised to $40 from $27 at Jefferies »

Jefferies analyst Eun…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 19

    Mar

NH

NantHealth

$7.54

-0.08 (-1.05%)

, MDRX

Allscripts

$12.05

-0.11 (-0.90%)

13:33
02/27/17
02/27
13:33
02/27/17
13:33
Hot Stocks
CTCA partners with Allscripts, NantHealth to launch Clinical Pathways »

Cancer Treatment Centers…

NH

NantHealth

$7.54

-0.08 (-1.05%)

MDRX

Allscripts

$12.05

-0.11 (-0.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Mar

VRAY

ViewRay

$4.76

0.01 (0.21%)

13:30
02/27/17
02/27
13:30
02/27/17
13:30
Recommendations
ViewRay analyst commentary  »

ViewRay price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 06

    Mar

AIG

AIG

$63.97

0.34 (0.53%)

13:29
02/27/17
02/27
13:29
02/27/17
13:29
Periodicals
AIG board to discuss whether to penalize or oust CEO over Q4 numbers, WSJ says »

AIG's directors are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 05

    Mar

HAIN

Hain Celestial

$34.61

-0.23 (-0.66%)

13:26
02/27/17
02/27
13:26
02/27/17
13:26
Options
Hain Celestial call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLUE

bluebird bio

$82.00

3.7 (4.73%)

13:19
02/27/17
02/27
13:19
02/27/17
13:19
Downgrade
bluebird bio rating change  »

Follow-up: bluebird bio…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

$NSD

NASDAQ Market Internals

13:17
02/27/17
02/27
13:17
02/27/17
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

13:16
02/27/17
02/27
13:16
02/27/17
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLUE

bluebird bio

$82.00

3.7 (4.73%)

13:15
02/27/17
02/27
13:15
02/27/17
13:15
Downgrade
bluebird bio rating change  »

bluebird bio downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

STM

STMicroelectronics

$15.49

0.485 (3.23%)

13:06
02/27/17
02/27
13:06
02/27/17
13:06
Options
STMicroelectronics call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XOM

Exxon Mobil

$81.47

0.385 (0.47%)

13:05
02/27/17
02/27
13:05
02/27/17
13:05
Periodicals
Exxon CEO sees rising Permian production, continued Russia presence, Forbes says »

Speaking in a Forbes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 01

    Mar

SAFM

Sanderson Farms

$94.44

-0.72 (-0.76%)

13:01
02/27/17
02/27
13:01
02/27/17
13:01
Conference/Events
Sanderson Farms management to meet with JPMorgan »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

DDAIF

Daimler AG

$72.92

-0.39 (-0.53%)

13:01
02/27/17
02/27
13:01
02/27/17
13:01
Hot Stocks
Daimler names Martin Daum head of Trucks, Buses divisions »

Daimler said its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MMM

3M

$186.67

-0.7399 (-0.39%)

13:00
02/27/17
02/27
13:00
02/27/17
13:00
Hot Stocks
IPTAB upholds validity of 3M Korean patent »

The Intellectual Property…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRVG

trivago

$12.85

-0.13 (-1.00%)

12:57
02/27/17
02/27
12:57
02/27/17
12:57
Conference/Events
trivago management to meet with JPMorgan »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

SSNLF

Samsung

, FB

Facebook

$135.44

0.08 (0.06%)

12:55
02/27/17
02/27
12:55
02/27/17
12:55
Hot Stocks
Samsung says new Facebook app available for Samsung TVs »

Samsung (SSNLF) announced…

SSNLF

Samsung

FB

Facebook

$135.44

0.08 (0.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 06

    Mar

  • 19

    Mar

  • 28

    Mar

SNAP

Snap Inc.

12:52
02/27/17
02/27
12:52
02/27/17
12:52
Hot Stocks
Snap Inc: Some Class A shares subject to separate lock-up »

In an amended IPO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

MRVL

Marvell

12:51
02/27/17
02/27
12:51
02/27/17
12:51
Options
Notable premium seller in Marvell Tech »

Notable premium seller in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 10

    Mar

  • 04

    Apr

  • 05

    Apr

WLL

Whiting Petroleum

$10.95

0.15 (1.39%)

12:46
02/27/17
02/27
12:46
02/27/17
12:46
Options
Whiting Petroleum call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

CLSD

Clearside Biomedical

$8.06

1.16 (16.81%)

12:45
02/27/17
02/27
12:45
02/27/17
12:45
Conference/Events
Clearside Biomedical has a conference call hosted by JPMorgan »

JPMorgan Analyst Rama…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

SBGSY

Schneider Electric

$13.49

-0.21 (-1.53%)

12:44
02/27/17
02/27
12:44
02/27/17
12:44
Conference/Events
Schneider Electric management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 02

    Mar

  • 03

    Mar

MTB

M&T Bank

$168.14

-0.535 (-0.32%)

12:37
02/27/17
02/27
12:37
02/27/17
12:37
Hot Stocks
M&T Bank announces passing of COO Mark Czarnecki »

M&T Bank announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.